MiRNA-based therapy for cancer: ID-1 suppresses the expression of tumor suppressor RECK via up regulation of its target gene, 6/February/2015, 22.55

Natural product-based therapy for B-cell cancer: Luteolin suppresses the expression of FOXP1 and inhibits Wnt/β-catenin signalling via up regulation of its target gene, 06/February/20145, 22.49
February 6, 2015
Vitamin-based cancer therapy: 1α,25-dihydroxyvitamin D(3) inhibits cancer development by suppressing the expression of nucleotide sanitizing enzyme MTH1/NUDT1, 06/February/2015, 23.02
February 6, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, MiRNA-based therapy for cancer: ID-1 suppresses the expression of tumor suppressor RECK via up regulation of its target gene, 6/February/2015, 22.54, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that ID-1, by increasing the expression of its target gene, it may suppress the expression of tumor suppressor RECK.  Thus, pharmacological formulations encompassing “ID-1 inhibitors” may be used to inhibit cancer development.

Amount: $ 300

Undisclosed information: How ID-1 suppresses the expression of tumor suppressor RECK.

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.